
Moderna (MRNA) Stock Forecast & Price Target
Moderna (MRNA) Analyst Ratings
Bulls say
Moderna is projected to experience significant revenue growth, with product sales estimated to rise from $1.73 billion in 2025 to $2.15 billion in 2026, indicating robust demand for its therapeutic offerings. The firm has strengthened its balance sheet through a $1.5 billion debt deal, which enhances its financial flexibility to capitalize on growth opportunities and navigate uncertainties. Additionally, improvements in manufacturing efficiency are expected to expand gross margins by 10% over the next three years, recovering from compressed levels and providing a solid foundation for future profitability.
Bears say
The financial outlook for Moderna appears negative primarily due to declining COVID-19 vaccine sales, which fell from $18 billion in 2022 to $6.7 billion in 2023, alongside reduced revenue guidance for 2025 attributed to waning vaccination rates. Additionally, the competitive landscape for RSV vaccines presents challenges, as approved products like Arexvy and Abrysvo limit the commercial potential of Moderna's mRESVIA. The valuation of Moderna's COVID and COVID+flu vaccine pipeline has decreased from $11.70 billion to $10.50 billion, indicating an overall contraction in expected future revenue, particularly as the pandemic transitions to an endemic phase.
This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.
Moderna (MRNA) Analyst Forecast & Price Prediction
Start investing in Moderna (MRNA)
Order type
Buy in
Order amount
Est. shares
0 shares